Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	001	US-D632801	02-15-2011	KYLE; Matthew R. et al.	
	002	US-4350156	09-21-1982	MALCHESKY; Paul S. et al.	
	003	US-4518584	05-21-1985	MARK; David F. et al.	
	004	US-4683195	11-27-1990	KARY; B. Mullisus et al.	
	005	US-4683202	07-28-1987	MULLIS; Kary B.	
	006	US-4708713	11-24-1987	LENTZ; M. Rigdon	
	007	US-4800159	01-24-1989	MULLIS; Kary B. et al.	
	008	US-5143854	09-01-1992	PIRRUNG; Michael C. et al.	
	009	US-5242974	09-07-1993	HOLMES; Christopher P.	
	010	US-5384261	01-24-1995	WINKLER; James L. et al.	
	011	US-5405783	04-11-1995	PIRRUNG; Michael C. et al.	
	012	US-5409818	04-25-1995	DAVEY; Cheryl et al.	
	013	US-5412087	05-02-1995	McGALL; Glenn H. et al.	
	014	US-5424186	06-13-1995	FODOR; Stephen P. A. et al.	
	015	US-5429807	07-04-1995	MATSON; Robert S. et al.	
	016	US-5436327	07-25-1995	SOUTHERN; Edwin M. et al.	
	017	US-5445934	08-29-1995	FODOR; Stephen P. A. et al.	
	018	US-5472672	12-05-1995	BRENNAN; Thomas M.	
	019	US-5527681	06-18-1996	HOLMES; Christopher P.	
	020	US-5529756	06-25-1996	BRENNAN; Thomas M.	
	021	US-5532128	07-02-1996	EGGERS; Mitchell D. et al.	
	022	US-5545531	08-13-1996	RAVA; Richard P. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	023	US-5554293	09-10-1996	UHOCH; John	
	024	US-5554501	09-10-1996	COASSIN; Peter J. [Us] et al.	
	025	US-5554527	09-10-1996	FICKENSCHER; Karl	
	026	US-5556752	09-17-1996	LOCKHART; David J. et al.	
	027	US-5561071	10-01-1996	HOLLENBERG; Cornelis P. et al.	
	028	US-5563120	10-08-1996	KUZNETSOV; Vladimir P.	
	029	US-5571639	11-05-1996	HUBBELL; Earl A. et al.	
	030	US-5593839	01-14-1997	HUBBELL; Earl A. et al.	
	031	US-5599695	02-04-1997	PEASE; R. Fabian et al.	
	032	US-5624711	04-29-1997	SUNDBERG; Steven A. et al.	
	033	US-5658734	08-19-1997	BROCK; Phillip JOE et al.	
	034	US-5700637	12-23-1997	SOUTHERN; Edwin	
	035	US-5728554	03-17-1998	BAYER; Robert J. et al.	
	036	US-5747251	05-05-1998	CARSON; Dennis A. et al.	
	037	US-5807522	09-15-1998	BROWN; Patrick O. et al.	
	038	US-5837832	11-17-1998	CHEE; Mark et al.	
	039	US-5876980	03-02-1999	DEFREES; Shawn et al.	
	040	US-5922577	07-13-1999	DEFREES; Shawn et al.	
	041	US-6004755	12-21-1999	WANG; Bruce	
	042	US-6010627	01-04-2000	HOOD; Iii, Andrew G.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	043	US-6030815	02-29-2000	DEFREES; Shawn et al.	
	044	US-6040138	03-21-2000	LOCKHART; David J. et al.	
	045	US-6040166	03-21-2000	ERLICH; Henry A. et al.	
	046	US-6045996	04-04-2000	CRONIN; Maureen T. et al.	
	047	US-6218114	04-17-2001	PECK; Konan et al.	
	048	US-6218122	04-17-2001	FRIEND; Stephen H. et al.	
	049	US-6271002	08-07-2001	LINSLEY; Peter S. et al.	
	050	US-6284460	09-04-2001	FODOR; Stephen P. A. et al.	
	051	US-6342157	01-29-2002	HOOD, III; Andrew G.	
	052	US-6472140	10-29-2002	TANZI; Rudolph E. et al.	
	053	US-6566331	05-20-2003	LEZDEY; Darren et al.	
	054	US-6607885	08-19-2003	LAROSSA; Robert A. et al.	
	055	US-6683155	01-27-2004	SILBIGER; Scott M. et al.	
	056	US-6806254	10-19-2004	GODBOLE; Shubhada D. et al.	
	057	US-6903201	06-07-2005	KEKUDA; Ramesh et al.	
	058	US-7011852	03-14-2006	SUKAVANESHVAR; Sivaprasad et al.	
	059	US-7186695	03-06-2007	HOGG; Philip John	
	060	US-7291450	11-06-2007	SOWEMIMO-COKER; Samuel O. et al.	
	061	US-7354515	04-08-2008	COULL; Thomas et al.	
	062	US-7485298	02-03-2009	POWELL; Michael	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	063	US-7709215	05-04-2010	SCUDERI; Gaetano J.	
	064	US-7803279	09-28-2010	COULL; Thomas et al.	
	065	US-7806845	10-05-2010	ARM; Douglas M. et al.	
	066	US-7858296	12-28-2010	SOWEMIMO-COKER; Samuel O. et al.	
	067	US-7888313	02-15-2011	GREENSPAN; Daniel S. et al.	
	068	US-7923203	04-12-2011	SOWEMIMO-COKER; Samuel O. et al.	
	069	US-7927344	04-19-2011	BURBA; Thomas A. et al.	
	070	US-8101077	01-24-2012	SUKAVANESHVAR; Sivaprasad et al.	
	071	US-8551068	10-08-2013	KYLE; Matthew R. et al.	
	072	US-9352021	05-31-2016	HANNA; Lewis et al.	
	073	US-10265388-B2	04-23-2019	HANNA; Lewis et al.	
	074	US-20020028207	03-07-2002	SRIVASTAVA; Pramod K. et al.	
	075	US-20020037290	03-28-2002	ARMEN; Garo H.	
	076	US-20030127390	07-10-2003	DAVIS; Richard C.	
	077	US-20030180722	09-25-2003	GODBOLE; Shubhada D. et al.	
	078	US-20030180835	09-25-2003	BAYER; Robert J.	
	079	US-20040072993	04-15-2004	SRIVASTAVA; Pramod K. et al.	
	080	US-20040138103	07-15-2004	PATT; Leonard M.	
	081	US-20050037432	02-17-2005	TORTORELLA; Mickey et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	082	US-20060025348	02-02-2006	PILON; Aprile et al.	
	083	US-20060165710	07-27-2006	SRIVASTAVA; Pramod K. et al.	
	084	US-20060204951	09-14-2006	FOLKMAN; Judah et al.	
	085	US-20070244306	10-18-2007	TANAHASHI; Kazuhiro et al.	
	086	US-20070259030	11-08-2007	DRAPEAU; Susan J.	
	087	US-20080040153	02-14-2008	DAVIS; Richard C.Jr	
	088	US-20080044852	02-21-2008	KANAYINKAL; Tessy et al.	
	089	US-20080269762	10-30-2008	SIMON; Bruce et al.	
	090	US-20090123452	05-14-2009	MADISON; Edwin L.	
	091	US-20090247456	10-01-2009	SRIVASTAVA; Pramod K. et al.	
	092	US-20100085606	04-08-2010	DAOS; Brenda	
	093	US-20100098684	04-22-2010	SCUDERI; Gaetano J. et al.	
	094	US-20110305663	12-15-2011	GOSSELIN; Michael L. et al.	
	095	US-20130059371	03-07-2013	SHEVITZ; Jerry	
	096	US-20190046617	02-14-2019	HANNA; Lewis	
	097	US-20190290741	09-26-2019	HANNA; Lewis et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]–Number[4]–Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	001	EP-1098664-B1	08-06-2003	OSPREY PHARMACEUTICALS LTD [CA]		☐
	002	EP-1320308-A1	06-25-2003	SALOMON SA [FR]	Abstract:	☒
	003	EP-2022506-A2	02-11-2009	CT INGENIERIA GENETICA BIOTECH [CU]		☐
	004	JP-2004256436-A	09-16-2004	KEIO GIJUKU., et al.	Abstract:	☒
	005	JP-S5732225-A	02-20-1982	TAKEDA CHEMICAL INDUSTRIES LTD.	Abstract:	☒
	006	WO-0226077-A1	04-04-2002	SALOMON SA [FR], et al.	Abstract:	☒
	007	WO-03015712-A2	02-27-2003	UNIV CONNECTICUT HEALTH CT [US], et al.		☐
	008	WO-03015712-A3	04-14-2005	UNIV CONNECTICUT HEALTH CT [US], et al.		☐
	009	WO-03031464-A2	04-17-2003	NEOSE TECHNOLOGIES INC [US], et al.		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]–Number[4]–Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	010	WO-03068822-A2	08-21-2003	MICROMET AG [DE], et al.		☐
	011	WO-03090686-A2	11-06-2003	UNIV CONNECTICUT HEALTH CT [US], et al.		☐
	012	WO-03099846-A2	12-04-2003	KECK GRADUATE INST [US], et al.		☐
	013	WO-03099846-A3	05-26-2005	KECK GRADUATE INST [US], et al.		☐
	014	WO-2004074454-A2	09-02-2004	UNIV CONNECTICUT HEALTH CT [US], et al.		☐
	015	WO-2006003388-A2	01-12-2006	DOMANTIS LTD [GB], et al.		☐
	016	WO-2006003388-A3	04-27-2006	DOMANTIS LTD [GB], et al.		☐
	017	WO-2006023911-A2	03-02-2006	BARRUETA ALBERTO GORROCHATEGUI [ES], et al.		☐
	018	WO-2006023911-A3	01-04-2007	BARRUETA ALBERTO GORROCHATEGUI [ES], et al.		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]–Number[4]–Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	019	WO-2006044614-A2	04-27-2006	SOPHERION THERAPEUTICS INC [US], et al.		☐
	020	WO-2006044614-A3	08-10-2006	SOPHERION THERAPEUTICS INC [US], et al.		☐
	021	WO-2007016250-A1	02-08-2007	GENVEC INC [US], et al.		☐
	022	WO-2008045148-A2	04-17-2008	CATALYST BIOSCIENCES INC [US], et al.		☐
	023	WO-2008045148-A3	10-16-2008	CATALYST BIOSCIENCES INC [US], et al.		☐
	024	WO-2008074029-A2	06-19-2008	BRIGHAM & WOMENS HOSPITAL [US], et al.		☐
	025	WO-2008074029-A3	12-11-2008	BRIGHAM & WOMENS HOSPITAL [US], et al.		☐
	026	WO-2010045024-A1	04-22-2010	CYTONICS CORP [US], et al.		☐
	027	WO-2010075249-A2	07-01-2010	GENENTECH INC [US], et al.		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]–Number[4]–Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	028	WO-2010075249-A3	10-07-2010	GENENTECH INC [US], et al.		☐
	029	WO-2010085606-A1	07-29-2010	UNIV CASE WESTERN RESERVE [US], et al.		☐
	030	WO-2013126587-A1	08-29-2013	CYTONICS CORP [US], et al.		☐
	031	WO-9736614-A1	10-09-1997	TERMAN DAVID S [US]		☐
	032	WO-9831826-A1	07-23-1998	CYTEL CORP [US], et al.		☐
	033	WO-9936507-A1	07-22-1999	GENITRIX LLC [US], et al.		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 10 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	001	A2M and Chronic Wounds. 7 pages. 02-18-2014.	☐
	002	A2M Peptide Biomarkers. 8 pgs (2005).	☐
	003	ABRAMS, et al. Hip Synovial Fluid Cytokine Profiling In Patients with and without Arthritis. Poster No. 1801. ORS 2012 Annual Meeting.	☐
	004	BARILLA, et al. Fibronectin fragments and their role in inflammatory arthritis. Semin Arthritis Rheum. 2000 Feb;29(4):252-65.	☐
	005	BEDI, et al. The effect of matrix metalloproteinase inhibition on tendon-to-bone healing in a rotator cuff repair model. J Shoulder Elbow Surg. 2010 Apr;19(3):384-91. Epub 2009 Oct 2.	☐
	006	BETTIN, Britta, et al., Removal of platelets from blood plasma to improve the quality of extracellular vesicle research. J Thromb Haemost 20(11):2679-2685 (2022).	☐
	007	BHATTACHARJEE, et al. The conformation-dependent interaction of alpha 2-macroglobulin with vascular endothelial growth factor. A novel mechanism of alpha 2-macroglobulin/growth factor binding. J Biol Chem. 2000 Sep 1;275(35):26806-11.	☐
	008	BINDER, R. Purification of alpha2-macroglobulin and the construction of immunogenic alpha2-macroglobulin-peptide complexes for use as cancer vaccines. Methods. 2004 Jan;32(1):29-31.	☐
	009	Biocompare Editor, Product Review for "Centricon® Centrifugal Filter Units from Millipore" (Dec. 21, 2006).	☐
	010	BORTH, W. Alpha 2-macroglobulin. A multifunctional binding and targeting protein with possible roles in immunity and autoimmunity. Ann N Y Acad Sci. 1994 Sep 10;737:267-72.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 11 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	011	BOWEN, et al. Bait region involvement in the dimer-dimer interface of human alpha 2-macroglobulin and in mediating gross conformational change. Evidence from cysteine variants that form interdimer disulfides. J Biol Chem. 1998 Jan 16;273(3):1825-31.	☐
	012	BRAUN, et al. The effect of local anaesthetics on synoviocytes: a possible indirect mechanism of chondrolysis. Knee Surg Sports Traumatol Arthrosc. 2012 Jun 21. 1468-74.	☐
	013	BROWNING, et al., "Platelet-rich plasma increases matrix metalloproteinases in cultures of human synovial fibroblasts," J Bone Joint Surg Am., 2012;94(23):e1721-7.	☐
	014	BURTON-WURSTER, et al. Fibronectin and water content of articular cartilage explants after partial depletion of proteoglycans. J Orthop Res. 1986;4(4):437-45.	☐
	015	CASTILLO, et al. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med. 2011;39(2):266-271.	☐
	016	COTE, et al. Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci U S A. 1983 Apr;80(7):2026-30.	☐
	017	CUELLAR, et al. Can Intra-articular cytokine profiling predict the development of knee pain? Four-year follow-up of asymptomatic controls. Poster No. 1793. ORS 2012 Annual Meeting.	☐
	018	CUELLAR, et al. Cytokine evaluation in individuals with low back pain using discographic lavage. Spine J. 2010 Mar;10(3):212-8.	☐
	019	CUELLAR, et al. Cytokine Expression in the Epidural Space: A Model of Non-compressive Disc Herniation-induced Inflammation. Spine (Phila Pa 1976). 2012 May 29. 38(1):17-23.	☐
	020	CUELLAR, et al. Cytokine profiling in acute anterior cruciate ligament injury. Arthroscopy. 2010 Oct;26(10):1296-301.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 12 | of | 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	021	CUELLAR, et al. Diagnostic utility of cytokine biomarkers in the evaluation of acute knee pain. J Bone Joint Surg Am. 2009 Oct;91(10):2313-20.	☐
	022	CUELLAR, et al. Does a fibronectin and aggrecan complex play a role in painful vertebral disks? PM R. 2013 Apr;5(4):297-302; quiz 302. doi: 10.1016/j.pmrj.2013.01.002. Epub 2013 Mar 13.	☐
	023	CUELLAR, et al. Is there a chondroprotective effect of autologous protease inhibitor concentrate on an osteoarthritis rabbit model? A pilot study. 11th Annual Pain Medicine Meeting. Miami, Florida. November 15, 2012.	☐
	024	Cytonics Publication Summary. 2 pages (2012).	☐
	025	DE GRAUW, et al. Arthrogenic lameness of the fetlock: synovial fluid markers of inflammation and cartilage turnover in relation to clinical joint pain. Equine Vet J. 2006 Jul;38(4):305-11.	☐
	026	DEMAILLE, et al. Human alpha-2 macroglobulin: isolation and composition (L alpha-2 macroglobuline humaine: isolement et composition). C R Seances Soc Biol Fil. 1970;164(3):626-31.	☐
	027	DEMIRAG, et al. Enhancement of tendon-bone healing of anterior cruciate ligament grafts by blockage of matrix metalloproteinases. J Bone Joint Surg Am. 2005 Nov;87(11):2401-10.	☒
	028	DEMIRAG, et al. The effect of alpha-2 macroglobulin on the healing of ruptured anterior cruciate ligament in rabbits. Connect Tissue Res. 2004;45(1):23-27.	☐
	029	DISSEMOND, et al. EPA made easy. Wounds International. 2013; 4(2):1-6.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 13 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	030	DUMFARTH, et al. Prophylactic low-energy shock wave therapy improves wound healing after vein harvesting for coronary artery bypass graft surgery: a prospective, randomized trial. Ann Thorac Surg. 2008 Dec;86(6):1909-13. doi: 10.1016/j.athoracsur.2008.07.117.	☐
	031	DUNN, et al. The alpha 2-macroglobulin of human plasma. I. Isolation and composition. J Biol Chem. 1967 Dec 10;242(23):5549-55.	☐
	032	EDSBERG, et al. Analysis of the proteomic profile of chronic pressure ulcers. Wound Repair Regen. 2012 May-Jun;20(3):378-401. doi: 10.1111/j.1524-475X.2012.00791.x.	☐
	033	EMING, et al. The inhibition of matrix metalloproteinase activity in chronic wounds by a polyacrylate superabsorber. Biomaterials. 2008 Jul;29(19):2932-40. doi: 10.1016/j.biomaterials.2008.03.029. Epub 2008 Apr 9.	☐
	034	Final Office Action dated 7/17/2019 for US Serial No.: 15/910,477.	☐
	035	FOSANG - ADAMTS-5: the story so far. Eur Cell Mater. 2008 Feb 5;15:11-26.	☐
	036	FRECHETTE, et al. Platelet-rich plasmas: growth factor content and roles in wound healing. J. Dent. Res. 2005;84(5):434-439.	☐
	037	FRESHNEY, I. Culture of Animal Cells: A Manual of Basic Technique. Wiley-Liss; 5th edition 2005.	☐
	038	GAJENDRAN, et al. Is the fibronectin-aggrecan complex present in cervical disk disease? PM R. 2011 Nov;3(11):1030-4. doi: 10.1016/j.pmrj.2011.07.003.	☐
	039	GHALE-NOIE, et al., High Serum Alpha-2-Macroglobulin Level in Patients with Osteonecrosis of the Femoral Head,Arch. Bone Jt. Surg., 2018, Vol. 6(3):219-224.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 14 | of | 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	040	GIBSON, et al. MMPs made easy. Wounds International. 2009; 1:1-6.	☐
	041	GOLISH, et al. Are persistently symptomatic vertebral compression fractures associated with abnormal inflammatory profiles? A prospective study. J Spinal Disord Tech. 2011 Apr;24(2):121-5.	☐
	042	GOLISH, et al. Functional outcome after lumbar epidural steroid injection is predicted by a complex of fibronectin and aggrecan. Proceedings of the NASS 25th Annual Meeting. The Spine Journal 10:29S-30S (2010).	☐
	043	GOLISH, et al. Outcome of lumbar epidural steroid injection is predicted by assay of a complex of fibronectin and aggrecan from epidural lavage. Spine (Phila Pa 1976). 2011 Aug 15;36(18):1464-9.	☐
	044	GREENWALD. Thirty-six years in the clinic without an MMP inhibitor. What hath collagenase wrought? Ann N Y Acad Sci. 1999 Jun 30;878:413-9.	☐
	045	GRINNELL, et al. Degradation of fibronectin and vitronectin in chronic wound fluid: analysis by cell blotting, immunoblotting, and cell adhesion assays. J Invest Dermatol. 1992 Apr;98(4):410-6.	☐
	046	GRINNELL, et al. Fibronectin degradation in chronic wounds depends on the relative levels of elastase, alpha1-proteinase inhibitor, and alpha2-macroglobulin. J Invest Dermatol. 1996 Feb;106(2):335-41.	☐
	047	HADLER, et al. Protease Inhibitors in Inflammatory Synovial effusions. Annals of Rheumatic diseases. 1981; 40:55-59.	☐
	048	HASHIMOTO, et al. ADAMTS4 (aggrecanase-1) interaction with the C-terminal domain of fibronectin inhibits proteolysis of aggrecan. J Biol Chem. 2004 Jul 30;279(31):32483-91. Epub 2004 May 25.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 15 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	049	HENIKOFF, Steven. et al. Amino Acid Substitution Matrices From Protein Blocks. PNAS USA 89(22):10915-10919 (1992).	☐
	050	HOFHEINZ, E. EUREKA! RUSH RESEARCHERS FIND BREAKTHROUGH IN OA. January 3, 2013. Available at http://ryortho.com/breaking/eureka-rush-researchers-find-breakthrough-in-oa/. Accessed 07/11/2013.	☐
	051	HOLLAND et al. Detection of specific polymerase chain reaction product by utilizing the 5' ---- 3' exonuclease activity of Thermus aquaticus DNA polymerase. PNAS USA 88(16):7276-7280 (1991).	☐
	052	HONJO, et al. Kinetics of {alpha}2-macroglobulin and {alpha}1-acid glycoprotein in rats subjected to repeated acute inflammatory stimulation. Lab Anim. 2010 Apr;44(2):150-4. Epub 2009 Oct 26.	☐
	053	HUNT, et al. Inflammatory Cytokines in the Painful Ankle Joint: Arthritis and Osteochondral Lesions. (2012).	☐
	054	HUSE, et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science. 1989 Dec 8;246(4935):1275-81.	☐
	055	IKAI, et al. A recombinant bait region mutant of human alpha2-macroglobulin exhibiting an altered proteinase-inhibiting spectrum. Cytotechnology. 1999 Sep;31(1-2):53-60. doi: 10.1023/A:1008011919876.	☐
	056	IMBER, et al. Clearance and Binding of Two Electrophoretic 'fast' forms of Human A2-macroglobulin. J. Bio. Chem. August 10, 1981; 256(15):8134-8139.	☐
	057	INADA, et al. Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification. Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17192-7. Epub 2004 Nov 24.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 16 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	058	INMAN, E. Researchers create "truth serum" to explain knee pain. http://www.stanforddaily.com/2011/02/17/researchers-create-%E2%80%9Ctruth-serum%E2%80%9D-to-explain-knee-pain/ Accessed 12/03/2014.	☐
	059	International Search Report and Written Opinion dated August 7, 2013 for PCT/US2013/027159.	☐
	060	JACKSON. Cytokine Biomarkers in Orthopedics Offer An Enormous Diagnosis and Prognosis Potential. Orthopedics Today. January 2010. 3 pgs.	☐
	061	KÖHLER, G. et al. Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity. Nature 256(5517):495-497 (1975).	☐
	062	KIMMEL, et al. Preparation of cDNA and the generation of cDNA libraries: overview. Methods Enzymol. 1987;152:307-16.	☐
	063	KOZBOR, et al. Specific immunoglobulin production and enhanced tumorigenicity following ascites growth of human hybridomas. J Immunol Methods. 1985 Jul 16;81(1):31-42.	☐
	064	LIANG, et al. Distribution and cloning of eukaryotic mRNAs by means of differential display: refinements and optimization. Nucleic Acids Res. 1993 Jul 11;21(14):3269-75.	☐
	065	LINDENA, et al. Efficacy and safety of a polyester leukocyte removal filter for whole blood and red cell concentrate filtration. J Clin Chem Clin Biochem. 1989 May;27(5):331-6.	☐
	066	LINDHORST, et al. Increase in degraded collagen type II in synovial fluid early in the rabbit meniscectomy model of osteoarthritis. Osteoarthritis Cartilage. 2005 Feb;13(2):139-45.	☐
	067	LOBMANN, et al. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia. 2002 Jul;45(7):1011-6. Epub 2002 May 25.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 17 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	068	LOBMANN, et al. Proteases and the diabetic foot syndrome: mechanisms and therapeutic implications. Diabetes Care. 2005 Feb;28(2):461-71.	☐
	069	LUAN, et al. Inhibition of ADAMTS-7 and ADAMTS-12 degradation of cartilage oligomeric matrix protein by alpha-2-macroglobulin. Osteoarthritis Cartilage. 2008 Nov;16(11):1413-20. Epub 2008 May 15.	☐
	070	MANIATIS, et al. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., USA 1982.	☐
	071	MASTERS, et al. Effects of nitric oxide releasing poly(vinyl alcohol) hydrogel dressings on dermal wound healing in diabetic mice. Wound Repair Regen. 2002 Sep-Oct;10(5):286-94.	☐
	072	MCCAFFERTY, et al. Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 1990 Dec 6;348(6301):552-4.	☐
	073	MILLER, et al. CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis. Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20602-7. doi: 10.1073/pnas.1209294110. Epub 2012 Nov 26.	☐
	074	MORRISON et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A. 1984 Nov;81(21):6851-5.	☐
	075	NAKAYAMA, et al. Removal of trypsin complexed alpha-2 macroglobulin by plasma fractionation. ASAIO Journal. 1993; M297-M300.	☐
	076	NEEDLEMAN, Saul B, and Christian D. Wunsch. A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins. Journal of Molecular Biology 48(3):443-453 (1970).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 18 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	077	NEUBERGER, Michael S. et al. Recombinant Antibodies Possessing Novel Effector Functions. Nature 312(5995):604-608 (1984).	☐
	078	NGUYEN, et al. Applications of platelet-rich plasma in musculoskeletal and sports medicine: An evidence-based approach. PM R. 2011;3(3):226-250.	☐
	079	Non-natural bait region of a variant A2M protein, SEQ ID 47, XP002778335, retrieved from EBI Accession No. GSP:BAS63734 (2013).	☐
	080	Notice of Allowance and Examiner's Amendment and Examiner-Initiated Interview Summary dated December 10, 2018, for US Serial No.: 14/380,234.	☐
	081	Notice of Allowance dated 12/8/18 for US Serial No.: 14/380,234.	☐
	082	Office action dated 01/06/2017 for US Application No. 14/380,234.	☐
	083	Office action dated 05/26/2016 for US Application No. 14/380,234.	☐
	084	Office action dated 08/06/2015 for US Application No. 14/380,234.	☐
	085	Office action dated 08/11/2017 for US Application No. 14/380,234.	☐
	086	Office action dated 10/08/2015 for US Application No. 14/380,234.	☐
	087	Office Action dated 12/21/2017 for U.S. Patent Application No 14/380,234.	☐
	088	Office Action dated 3/5/19 for US Serial No.: 15/910,477.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 19 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	089	OHARA, et al. One-sided polymerase chain reaction: the amplification of cDNA. Proc Natl Acad Sci U S A. 1989 Aug;86(15):5673-7.	☐
	090	ORGANS, et al. A2M Prior Art. Technical and clinical aspects of cascade filtration plasma exchange (CFPE). 3pages.	☐
	091	PALMER, Andre, et al., Tangential flow filtration of hemoglobin. Biotechnol Prog 5(1):189-199 (2009).	☐
	092	PCT/US2013/027159 International Preliminary Report on Patentability dated September 4, 2014.	☐
	093	Plasmaflo: OP series, Asahi hollow fiber plasma seprarator. Asahi Kasei Medical Co., Ltd. January 01/2012. www.asahi-kasei.co.jp/medical/en/pdf/apheresis/plasmaflo-op_catalog.pdf.	☐
	094	POLLER, et al. Cloning of the human alpha 2-macroglobulin gene and detection of mutations in two functional domains: the bait region and the thiolester site. Hum Genet. 1992 Jan;88(3):313-9.	☐
	095	POLLER, et al. Sequence polymorphism in the human alpha-2-macroglobulin (A2M) gene. Nucleic Acids Research. 2001; 19(1):198.	☐
	096	PR Newswire. Interpore Cross Receives FDA Clearance to Market New Device That Simplifies AGF(TM) Process. New York. August 22, 2022:1.	☐
	097	QUARANTA, et al. Technical and clinical aspects of cascade filtration plasma exchange (CFPE). Int J Artif Organs. 1983 Nov;6(6):309-14.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 20 | of | 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	098	RAO, et al. Alpha 1-antitrypsin is degraded and non-functional in chronic wounds but intact and functional in acute wounds: the inhibitor protects fibronectin from degradation by chronic wound fluid enzymes. J Invest Dermatol. 1995 Oct;105(4):572-8.	☐
	099	RAYMENT, et al. Attenuation of protease activity in chronic wound fluid with bisphosphonate-functionalised hydrogels. Biomaterials. 2008 Apr;29(12):1785-95. doi: 10.1016/j.biomaterials.2007.12.043. Epub 2008 Jan 31.	☐
	100	Re: Cytonics Patent Status and Strategy Summary letter. McHale & Slavin, P.A. Dated 03/23/2011. 37 pages.	☐
	101	Rheofilter ER-4000. Asahi Kasei Medical Co., Ltd. January 01/2012. www.asahi-kasei.co.jp/medical/en/pdf/apheresis/rheofilter-er_catalog.pdf.	☐
	102	ROMPAEY, et al. Design of a new protease inhibitor by the manipulation of the bait region of alpha 2-macroglobulin: inhibition of the tobacco etch virus protease by mutant alpha 2-macroglobulin. Biochem J. 1995 Nov 15;312 (Pt 1):191-5.	☐
	103	ROUKIS, et al. Autologous platelet-rich plasma for wound and osseous healing: a review of the literature and commercially available products. Adv Ther. 2006 Mar-Apr;23(2):218-37.	☐
	104	SAN GIOVANNI, et al. Correlation of intra-articular ankle pathology with cytokine biomarkers and matrix degradation products. Foot Ankle Int. 2012 Aug;33(8):627-31.	☐
	105	SANCHEZ, et al. Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee OA: a retrospective cohort study. Clin Exp Rheumatol. 2008 Sep-Oct;26(5):910-3.	☐
	106	SATO, et al. Relationship of calcitonin gene-related peptide in synovial tissues and temporomandibular joint pain in humans. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Nov;98(5):533-40.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 21 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	107	SCHAEFER. Gene Cloning and Analysis: Current Innovations, 1997 pp 99-115.	☐
	108	SCOPES. Protein purification: Principles and Practice, Springer-Verlag (1994).	☐
	109	SCUDERI, et al. A critical evaluation of discography in patients with lumbar intervertebral disc disease. Spine J. 2008 Jul-Aug;8(4):624-9. Epub 2007 Jan 10.	☐
	110	SCUDERI, et al. Cytokine assay of the epidural space lavage in patients with lumbar intervertebral disk herniation and radiculopathy. J Spinal Disord Tech. 2006 Jun;19(4):266-9.	☐
	111	SCUDERI, et al. Epidural interferon gamma-immunoreactivity: a biomarker for lumbar nerve root irritation. Spine (Phila Pa 1976). 2009 Oct 1;34(21):2311-7.	☐
	112	SCUDERI, et al. Identification of a complex between fibronectin and aggrecan G3 domain in synovial fluid of patients with painful meniscal pathology. Clin Biochem. 2010 Jul;43(10-11):808-14. Epub 2010 May 11.	☐
	113	SCUDERI, et al. Identification of a novel fibronectin-aggrecan complex in the synovial fluid of knees with painful meniscal injury. J Bone Joint Surg Am. 2011 Feb 16;93(4):336-40.	☐
	114	SHENA, et al. Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10614-9.	☐
	115	SHENA, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995 Oct 20;270(5235):467-70.	☐
	116	SNYDER, et al. Using a diagnostic tool to identify elevated protease activity levels in chronic and stalled wounds: a consensus panel discussion. Ostomy Wound Manage. 2011 Dec;57(12):36-46.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 22 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	117	SOTTRUP-JENSEN, et al., The alpha-macroglobulin bait region. Sequence diversity and localization of cleavage sites for proteinases in five mammalian alpha-macroglobulins, J. Biol Chem, Vol. 264, No. 27, 25 September 1989, pp. 15781-15789.	☐
	118	SOTTRUP-JENSEN, Lars, et al., Primary Structure of Human a2-Macroglobulin V. the complete Structure, The J Biological Chemistry, Vol. 259, No. 13, July 10, 1984, pp. 8318-8327.	☐
	119	SRIKRISHNA, et al. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia. 2009 Jul;11(7):615-28.	☐
	120	STANTON, et al. Investigating ADAMTS-mediated aggrecanolysis in mouse cartilage. Nat Protoc. 2011 Mar;6(3):388-404. Epub 2011 Mar 3.	☐
	121	STRUGLICS, et al. Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments. Osteoarthritis Cartilage. 2006 Feb;14(2):101-13. Epub 2005 Sep 26.	☐
	122	SUNDMAN, et al. Growth Factor and Catabolic Cytokine Concentrations Are Influenced by the Cellular Composition of Platelet-Rich Plasma. Am J Sports Med. 2011 Oct;39(10):2135-40. Epub 2011 Aug 16.	☐
	123	SWENSON, et al. Structural characterization of human alpha2-macroglobulin subunits. J Biol Chem. 1979 Jun 10;254(11):4452-6.	☐
	124	TAKEDA, Shun-Ichi. et al. Construction of Chimaeric Processed Immunoglobulin Genes Containing Mouse Variable and Human Constant Region Sequences. Nature 314(6010):452-454 (1985).	☐
	125	TCHETVERIKOV, et al. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis. 2004 Jul;63(7):881-3.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 23 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	126	TETLOW, et al. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum. 2001 Mar;44(3):585-94.	☐
	127	TRENGOVE, et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen. 1999 Nov-Dec;7(6):442-52.	☐
	128	TWINING, SS. Fluorescein isothiocyanate-labeled casein assay for proteolytic enzymes. Anal Biochem. 1984 Nov 15;143(1):30-4.	☐
	129	U.S. Serial No. 17/211,261 Office Action dated April 24, 2024.	☐
	130	VAN DEN DOLDER, et al. Platelet-rich plasma: quantification of growth factor levels and the effect on growth and differentiation of rat bone marrow cells. Tissue Eng. 2006;12(11):3067-3073.	☐
	131	VENTURA, et al. A pseudobiospecific hollow fiber cartridge for in vitro adsorbtion of autoantibodies from pathological serum. Braz. J. Chem. Eng. vol.17 n.4-7 São Paulo Dec. 2000.	☐
	132	WALLACE, et al., Plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis. Arthritis Rheum 22(7):703-710 (1979).	☐
	133	WANG, et al. Identification of α2-macroglobulin as a master inhibitor of cartilage-degrading factors that attenuates the progression of posttraumatic osteoarthritis. Arthritis Rheumatol. 2014 Jul;66(7):1843-53. doi: 10.1002/art.38576.	☐
	134	WARD, E Sally. et al. Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from Escherichia Coli. Nature 341(6242):544-546 (1989).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 24 of 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	135	WEIBRICH, et al. Curasan PRP kit vs. PCCS PRP system. Collection efficiency and platelet counts of two different methods for the preparation of platelet-rich plasma. Clin Oral Implants Res. 2002 Aug;13(4):437-43.	☐
	136	WEIBRICH, et al. Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count. J Craniomaxillofac Surg. 2002;30(2):97-102.	☐
	137	WEIBRICH, et al. Growth factor levels in the platelet-rich plasma produced by 2 different methods: curasan-type PRP kit versus PCCS PRP system. Int J Oral Maxillofac Implants. 2002;17(2):184-190.	☐
	138	WILD. Biomarkers Predict Response to Steroid Injections In Radiculopathy Patients. January 2011; volume 37:1. http://www.anesthesiologynews.com/default.aspx. Accessed on 12/05/2014. 2 pages.	☐
	139	WILDEBOER, et al. Specific protease activity indicates the degree of Pseudomonas aeruginosa infection in chronic infected wounds. Eur J Clin Microbiol Infect Dis. 2012 Sep;31(9):2183-9. doi: 10.1007/s10096-012-1553-6. Epub 2012 Jan 26.	☐
	140	WOODELL-MAY, et al. Autologous protein solution inhibits MMP-13 production by IL-1β and TNFα-stimulated human articular chondrocytes. J Orthop Res. 2011 Sep;29(9):1320-6. doi: 10.1002/jor.21384. Epub 2011 Mar 15.	☐
	141	WYSOCKi, et al. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol. 1993 Jul;101(1):64-8.	☐
	142	YAGER, et al. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. Wound Repair and Regeneration. 1997; 5:23-32.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 25 | of | 27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	143	ZACK, et al. Identification of fibronectin neoepitopes present in human osteoarthritic cartilage. Arthritis Rheum. 2006 Sep;54(9):2912-22.	☐
	144	ZHANG, et al. Inhibition of bone morphogenetic protein 1 by native and altered forms of alpha2-macroglobulin. J Biol Chem. 2006 Dec 22;281(51):39096-104. Epub 2006 Oct 27.	☐
	145	ZHANG, et al. Phosphoprotein analysis using antibodies broadly reactive against phosphorylated motifs. J Biol Chem. 2002 Oct 18;277(42):39379-87. Epub 2002 Jul 31.	☐
	146	ZHANG, et al. Poster 108: Characterization of fibronectin fragments in human surgical intervertebral disk specimens. Archives of Phyisical medicine and rehabilitation. 2007; 88(9):e40.	☐
	147	ZHANG, Yang et al., Targeted designed variants of alpha-2-macroglobulin (A2M) attenuate cartilage degeneration in a rat model of osteoarthritis induced by anterior cruciate ligament transection," Arthritis Research & Therapy, Vol. 19, No. 1, 25 July 2017 XP055452623. .	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	26	of	27

Complete if Known	
Application Number	18/777,657
Filing Date	07-19-2024
First Named Inventor	LEWIS; Hanna
Art Unit	OPAP
Examiner Name	CENTRAL, DOCKET
Attorney Docket Number	37151-701.303

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Koyi Yoon/	Date (YYYY-MM-DD)	2025-03-25
Name/Print	Koyi Yoon	Registration Number	77,260

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.